Recently,LEADBIO, a regenerative repair materials and artificial organs R&D platform based in Hangzhou, has completed its nearly RMB 100 million Series A round of financing.This round of financing was led by Panlin Capital, with investments from Tailong Investment and BGI Win-Win. Existing shareholders Taiyu Investment and Boxin Capital also continued to increase their investments in this round.

Under the capital winter,As a next-generation innovative medical device company,LEADBIO's successful completion of a large-scale financing round fully demonstrates the capital market's high recognition and optimism towards its team and the specific niche it operates in.

The funds from this Series A round will be mainly used for the registrational clinical trials of LEADBIO's bio-artificial blood vessels, while continuously advancing the research and development of other pipelines and further improving the construction of the company’s technology transfer platform.

It is reported that LEADBIO was founded by a senior team in the medical industry and the current director of the State Key Laboratory of Drug Chemistry and Biology at Nankai University.Professor Deling KongCo-founded, the company is positioned to become an internationally leading regenerative medicine product company and a platform for the transformation of cutting-edge medical device technologies.

LEADBIO's Bio-artificial Vessel, based on the innovative technology and manufacturing process fully independently developed by Professor Kong Deling's team, achieves the organic combination of polymer materials with decellularized matrix possessing bioactivity. This technical approach not only provides the artificial vessel with excellent mechanical properties but also ensures better biocompatibility and long-term patency. After implantation in patients, the meticulously designed scaffold structure and extracellular matrix layer promote the adhesion, proliferation, and migration of endothelial cells, ultimately enabling rapid endothelialization of the artificial vessel, thereby significantly reducing the incidence of vascular stenosis and occlusion.

Currently, in the completed controlled formal animal trials,LEADBIO's artificial blood vessels demonstrate significantly superior performance compared to those made from polymer materials.In the research-based clinical trial of arteriovenous fistula involving 20 enrolled patients that has already been completed, LEADBIO's biological artificial blood vessel also demonstrated excellent clinical results. According to information disclosed by LEADBIO, a registration clinical trial for this product is about to be launched.

In addition, the results of earlier studies indicate that LEADBIOBiotypic artificial blood vessels have great application potential in the indication of coronary artery bypass grafting.Currently, LEADBIO is collaborating with top cardiac surgery teams in China to conduct preclinical research in this direction.

As a platform enterprise focused on the transformation of cutting-edge scientific and technological achievements, LEADBIO adheres to the principles of "technology platform sharing" and "product complementarity." It has currently established three major technological platforms: decellularized matrix, 3D printing, and hydrogel. Multiple products incubated under this platform will soon enter the registration clinical trial stage.

Among them, LEADBIO's radiation therapy isolation protection hydrogel product was co-developed with the Institute of Biomedical Engineering of the Chinese Academy of Medical Sciences. This is another significant medical device product that LEADBIO has successfully translated from collaboration with domestic research institutions, following its bio-based artificial blood vessel.

Professor Kong Deling, Chairman of LEADBIOStated: "First of all, we would like to express our heartfelt gratitude to the Series A investment institutions led by Panlin Capital for their strong support in this round of financing; LEADBIO, like many innovative companies, takes original technological innovation as the core driving force for enterprise development. On the other hand, it also incorporates more communication on clinical market demands and the R&D capabilities and cutting-edge achievements of various scientific research institutes. LEADBIO's 'small-caliber biological artificial blood vessel' is the first technology transfer product under this development strategy. This project has not only demonstrated excellent preliminary clinical research results but also participated in a major R&D plan by the Ministry of Science and Technology. In the future, the company will strive to bring more revolutionary products to patients through the basic research base of 'LEADBIO-Nankai University Joint Laboratory'. At the same time, we hope to leverage our management experience and transformation experience in cutting-edge biotechnology to help more scientists achieve the industrialization of scientific and technological achievements, and more efficiently convert more research results into innovative medical device products that meet clinical needs."

As the lead investor of LEADBIO's Series A financing, Li Yuhui, founding managing partner of Panlin CapitalRepresentative Statement: "LEADBIO is a successful case of scientific and technological achievement transformation in the field of regenerative medicine tissue engineering in China, and also a typical 'source innovation' enterprise in the eyes of Panlin. Its product technology platform is based on Professor Deling Kong's nearly 20 years of scientific research exploration. By combining the globally pioneering technical approach of 3D scaffold printing with subcutaneous implantation in animals, it has resolved the technical challenges of small-diameter blood vessels and ensured the continuous expansion of the product pipeline. Particularly commendable is that the company’s R&D progress for its coronary artery bypass regeneration vessels is internationally leading, and if successful, will be of epoch-making significance. We look forward to the company, under the leadership of the highly complementary management team of Chairman Professor Deling Kong and CEO Pengyun Xu, smoothly advancing the clinical pipelines of arteriovenous fistula and coronary artery bypass, and further evolving into a globally leading R&D enterprise for small-diameter regenerative blood vessels."

Dr. Jirong Ji, Founder and General Manager of Taiyu InvestmentSaid: "The biological artificial blood vessel of LEADBIO has been verified in clinical trials, with excellent surgical handling characteristics and a high long-term patency rate, meeting the clinical needs of dialysis patients. It is hoped that it can be launched as soon as possible to provide a new high-quality option for dialysis patients in China."

Sun Jun, Executive Director of Tailong Investment"It shows that the artificial blood vessel products have a huge market for import substitution. Existing research data indicate that LEADBIO's biological artificial blood vessels demonstrate significant clinical advantages compared to imported polymer material blood vessel products. They belong to the next generation of products in the artificial blood vessel field and are expected to reshape the competitive landscape in this area."

LeadBio Capital Cong BoRepresentative stated: "LEADBIO's biotechnology has global leadership and is one of the few companies in China that fully relies on self-developed products to solve clinical problems. The company’s biological artificial blood vessels have been validated for product efficacy and safety in dialysis fistula and have completed product layout in areas such as coronary artery bypass and peripheral bypass. Boxing Capital continued its investment in this round, fully trusting the company’s team capabilities and firmly optimistic about the future development opportunities of the products."

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

Powerful Alliance! The Most Advanced Superconducting Heavy Ion Technology Enters China

How Should Endoscopy Companies Efficiently Empower Precision Medicine?

CIIE Review: Endoscopes + Surgical Robots

Asia-Pacific's First, "King of Rigid Endoscopes" Makes a Big Move

Giant in Vascular Interventions Announces Leadership Change

Innovative Medical "Black Tech", Boston Scientific Showcases Multiple Products at CIIE

Global First: Siemens Healthineers' 4D Volumetric Intracardiac Echocardiography Catheter Debuts at CIIE

Just now, "MicroPort" Two Listed Companies Change CEOs

Siemens Healthineers Debuts Multiple Heavyweight New Products for the Sixth Consecutive Year at the CIIE

Breaking: Medtronic's Partner May Be Delisted

BusinessBusiness cooperation email: qxzj@landianyiliao.com